1133425-75-8
1133425-75-8
Chemical Structure
Deferasirox-d4
- CAS No.: 1133425-75-8
- Formula:C21H11D4N3O4
- Molecular Weight:377.39
IUPAC Name: 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic-2,3,5,6-d4 acid
InChIKey: BOFQWVMAQOTZIW-IRYCTXJYSA-N
SMILES: OC1=C(C=CC=C1)C2=NC(C3=C(C=CC=C3)O)=NN2C4=C([2H])C([2H])=C(C([2H])=C4[2H])C(O)=O
Biological Activity: Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deferasirox-d4 | Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deferasirox (Standard) | ≥98% | Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deferasirox-13C6 | Deferasirox-13C6 (ICL 670-13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deferasirox | 99.86% | Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45. [Content Brief]
- [3]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5. [Content Brief]
